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Background: Despite advances in drug-eluting stent (DES) technology, diabetic
patients remain at higher risk of developing in-stent restenosis due to neointimal
hyperplasia as compared to non-diabetics. The everolimus eluting ABSORB™
Bioresorbable Vascular Scaffold (BVS) is a new generation devices developed to
prevent in-stent restenosis while minimizing chronic irritation of the vessel wall as
may be induced by metallic stents. Therefore, the effect of ABSORB™ BVS in a swine
coronary model with Diabetes Mellitus (DM) is studied.
Methods: In the present study 8 juvenile, male pigs were rendered non-insulin-
dependent (DM) by streptozotocin infusion (80 mg/kg). Seven non-diabetic (non-DM)
swine were used as controls; all animals received an atherogenic diet. At 9 months
study duration, 32 ABSORB™ BVS were implanted under QCA and OCT guidance
(balloon/artery ratio 1.1:1) in the coronary arteries. Immediately post-implantation and
at 3 months follow-up (FU), the scaffolded segment was imaged by OCT. Quantitative
analysis was performed by measuring lumen (LA), scaffold (SA), black core area of
the struts and neointimal (NIH) areas. NIH area=(SA-[LA+Black core area]).
Results: In total, 28 scaffolds in 13 pigs (DM: n=8; non-DM: n=5) were successfully
imaged at both timepoints. Baseline vessel and procedural characteristics were similar
between the 2 groups. Lumen and scaffold areas at baseline were 8.34±0.58mm2 vs
8.49±0.57mm2 (p=0.49) and 8.51±0.57mm2 vs 8.67±0.54mm2 (p=0.47) in DM vs non-
DM. However, at 3 mo FU, the neointimal area was slightly, but significantly larger in
DM as compared to non-DM (4.53±0.54mm2 vs 4.08±0.57mm2, p<0.05).
Conclusion: Quantitative OCT analysis 3 months after ABSORB™ BVS implantation
showed only a small increase in neointimal area in DM vs non-DM swine, indicating
that this Everolimus eluting platform performs well in a background of Diabetes
Mellitus. This response to ABSORB™ BVS is a new finding.
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Background: The aims of this study were to determine the interactive effect of
revascularization and optimal medical therapy (OMT) in patients with acute myocardial
infarction (AMI) complicated by congestive heart failure (CHF) on 6-month major
adverse cardiac events (MACE).
Methods: Between November 2005 and January 2008, 14,871 patients suspected AMI
were included from the Korea AMI Registry, and 9,470 patients (6,649 men; mean age
= 63.0 ± 12.5 years-old) followed up 6-month were finally analyzed. Of these patients,
2,595 (27.4%) patients had CHF (Killip class II-IV) at presentation. The 6-month
MACE was defined as death, nonfatal MI, and revascularization.
Results: Patients were categorized into 4 groups based on treatment modalities;
revascularization and OMT. Patients underwent revascularization and received OMT
had the lowest 6-month MACE (6.1%) and mortality (3.1%). The revascularized and
non-OMT patients had significantly lower 6-month MACE (14.0% versus 24.3%,
p<0.001) and mortality (11.4% versus 18.0%, p<0.001) compared with the non-
revascularized and OMT patients. Among non-CHF, compared with revascularized
and OMT group, there was no significant difference in 6-month MACE in
revascularized and non-OMT group (adjusted hazard ratio [HR] 1.235, 95% confidence
interval [CI] 0.967 to 1.578, p=0.091), whereas non-revascularized and OMT group
had significantly higher 6-month MACE (adjusted HR 2.437, 95% CI 1.416 to 4.197,
p=0.001) after adjustment for confounding variables in Cox proportional hazard model.
Among CHF patients, compared with revascularized and OMT group, there was no
significant difference in 6-month MACE in non-revascularized and OMT group
(adjusted HR 1.721, 95% CI 0.953 to 3.111, p=0.072), whereas revascularized and
non-OMT group had significantly higher 6-month MACE (adjusted HR 1.408, 95%
CI 1.026 to 1.931, p=0.034).
Conclusion: More assertive revascularization in non-CHF patients and more use of
OMT in CHF patients are required for reducing 6-month MACE in post-MI patients.
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Background: The aim of the study was to assess the impact of revascularization for
non-infarct arteries in patients with ST-segment elevation myocardial infarction
(STEMI) combined with hemodynamic instability.
Methods: We analyzed 4,697 consecutive patients with STEMI who had undergone
PCI from 2005 to 2008 and selected those with cardiogenic shock and multivessel
disease (n=354). Rates of cardiac death, nonfatal myocardial infarction and repeat
revascularization (MACEs) at 1 and 12 months after index PCI were compared between
patients who underwent either multivessel revascularization (MVR)(n=139)or
revascularization of infarct-related artery only(IRA)(n=215).
Results: There were no significant differences in baseline clinical and angiographic
characteristics except target vessel. Total MACE rates at 1 year were similar between
groups (p=0.292). the MVR group had a higher rate of repeat revascularization at 12
months(5.0% vs. 1.4%, p=0.043). In right coronary artery (RCA) subgroup, MVR
showed lower mortality than IRA only at 1-year follow-up (2.5% vs.16.0%, p=0.002),
and RCA was a strong predictor of survival in MVR (HR: 10.50, Cl: 1.25 – 88.1,
p=0.03).
Conclusion: These data suggest that performing MVR for patients with STEMI and
cardiogenic shock does not improve 1-year survival rate and even increases
revascularization rate. However, RCA as index vessel could be an important factor on
MVR clinical outcome in hemodynamic compromised STEMI patients.
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